ACADIA Pharmaceuticals, Inc. (NASDAQ:ACAD)

CAPS Rating: 2 out of 5

The Company is a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule drugs for the treatment of central nervous system disorders.

Results 1 - 20 of 49 : 1 2 3 Next »

Recs

0
Member Avatar OklaBoston (65.97) Submitted: 4/23/2016 11:24:53 PM : Underperform Start Price: $33.94 ACAD Score: +18.72

Deteriorating technicals and dreadful valuations. Only a matter of time until it falls below $10.00, IMO.

Recs

0
Member Avatar Ryusofly (< 20) Submitted: 4/18/2016 1:24:34 AM : Outperform Start Price: $29.18 ACAD Score: -7.22

Fda approval. On numbula

Recs

0
Member Avatar horsetowater (< 20) Submitted: 3/28/2016 1:58:53 PM : Underperform Start Price: $24.65 ACAD Score: -9.16

Not a prayer in the 3-29-2016 FDA AdCom...

Recs

0
Member Avatar gcaderas (72.67) Submitted: 3/11/2016 7:11:33 AM : Underperform Start Price: $19.48 ACAD Score: -37.02

Qtr (03/16) Qtr (06/16) FY (12/16) FY (12/17)
Average Estimate $-0.40 $-0.45 $-1.24 $-1.02
Number of Analysts 5 3 7 4
High Estimate $-0.35 $-0.42 $0.57 $-0.54
Low Estimate $-0.44 $-0.47 $-1.78 $-1.55
Prior Year $-0.40 $-0.39 $-1.63 $-1.24
Growth Rate (Year over Year) 0.50% -15.38% 23.93% 17.34%

Recs

0
Member Avatar 78taxs (< 20) Submitted: 1/31/2016 3:53:25 AM : Outperform Start Price: $20.80 ACAD Score: +23.45

This drug is need it will soon be a go it did go on for a long time to get things right and they are there.

Recs

0
Member Avatar ZekelHealthcare (< 20) Submitted: 1/6/2016 12:35:51 PM : Outperform Start Price: $29.82 ACAD Score: -12.02

Healthcare up tick

Recs

0
Member Avatar 1russianguy (38.19) Submitted: 8/20/2015 3:29:53 PM : Outperform Start Price: $34.87 ACAD Score: -24.03

Playing for a bounce from a correction.

Recs

0
Member Avatar TMFTypeoh (77.21) Submitted: 6/24/2015 11:57:16 AM : Outperform Start Price: $42.96 ACAD Score: -34.07

Winner with a good looking pipeline.

Recs

0
Member Avatar NuclearSteve (66.83) Submitted: 4/7/2015 12:54:02 PM : Outperform Start Price: $33.41 ACAD Score: -17.40

It is time to own it again after they got shellacked for missing the NDA a second time.

Recs

1
Member Avatar drugtrader (89.05) Submitted: 2/27/2015 8:28:05 PM : Outperform Start Price: $32.41 ACAD Score: -17.01

This one could be really undervalued and likely hit $100 someday.

Great drug!

Recs

1
Member Avatar evanation (< 20) Submitted: 2/27/2015 5:49:21 PM : Outperform Start Price: $38.25 ACAD Score: -26.52

This is a speculative biotech, but is close to getting their first drug out.

Recs

0
Member Avatar craze191st (47.71) Submitted: 10/17/2014 2:35:21 PM : Outperform Start Price: $25.83 ACAD Score: -4.17

Primavanserin is sure to be a hit.

Recs

0
Member Avatar sam5454 (< 20) Submitted: 6/26/2014 7:25:26 PM : Outperform Start Price: $22.65 ACAD Score: +14.30

FDA approval is almost certain. A buyer will appear.

Recs

0
Member Avatar molmaemo (< 20) Submitted: 4/22/2014 11:23:26 AM : Outperform Start Price: $21.01 ACAD Score: +19.75

Every neighborhood block has a home for Alzheimer's patients. WE NEED TO MAKE THIS WORK. These diseases are overwhelming health care!

Recs

0
Member Avatar 2win (< 20) Submitted: 1/11/2014 12:36:28 PM : Outperform Start Price: $23.94 ACAD Score: +1.42

rebuying lower

Recs

0
Member Avatar pcguy (< 20) Submitted: 11/23/2013 2:54:50 AM : Underperform Start Price: $22.34 ACAD Score: -7.92

Catalysts too far out. Stock overbought.

Recs

0
Member Avatar SqwiiTrader (< 20) Submitted: 11/9/2013 6:11:31 PM : Underperform Start Price: $21.78 ACAD Score: -8.47

top hs pattern

Recs

0
Member Avatar stardog900 (< 20) Submitted: 7/27/2013 2:08:23 PM : Outperform Start Price: $18.51 ACAD Score: +24.62

If trials are successful, as is anticipated, this stock should outperform the S&P 500 greatly over the next year or two. Potential for large increase in value long term.

Recs

0
Member Avatar TheStockDoctor (< 20) Submitted: 6/11/2013 7:14:01 AM : Outperform Start Price: $19.57 ACAD Score: +12.70

Multiple new compounds fill an open void. Little price competition will protect profit margins.

Recs

0
Member Avatar TMFBiologyFool (92.45) Submitted: 11/27/2012 4:18:10 PM : Underperform Start Price: $4.92 ACAD Score: -403.14

No catalyst for awhile. And second phase 3 isn't a sure thing. Placebo effect is hard to beat twice.

Results 1 - 20 of 49 : 1 2 3 Next »

Featured Broker Partners